Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin

Published:2010-03-08 Issue:12 Volume:31 Page:1346-1353
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

MANGIA A.,DALGARD O.,MINERVA N.,VERBAAN H.,BACCA D.,RING-LARSEN H.,COPETTI M.,CARRETTA V.,PIAZZOLLA V.,COZZOLONGO R.,MOTTOLA L.,ANDRIULLI A.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2010.04290.x/fullpdf

Reference29 articles.

1. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study;Dalgard;Hepatology,2004

2. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3;Mangia;New Engl J Med,2005

3. Peginterferon alfa 2a [40 kd] and ribavirin for 16 weeks in patients with genotype 2 or 3 chronic hepatitis C;Von Wagner;Gastroenterology,2005

4. A randomised study on PegInterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C;Yu;Gut,2007

5. A randomized controlled trial of pegylated interferon alfa and ribavirin for 14 vs 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response;Dalgard;Hepatology,2008

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ARRIBA concept: adequate resorption of ribavirin;Antiviral Therapy;2015

2. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions;Liver International;2013-11-20

3. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin;Hepatology;2012-06-29

4. Assessment of the treatment of chronic hepatitis C in the state of Mato Grosso, central Brazil;Memórias do Instituto Oswaldo Cruz;2012-03

5. Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis;Journal of Hepatology;2012-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3